文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > The Diagnosis and Management of Non-alcoholic
侵权投诉

The Diagnosis and Management of Non-alcoholic

The Diagnosis and Management of Non-alcoholic

nature publishing group

PRACTICE GUIDELINES

811

The Diagnosis and Management of Non-alcoholic

Fatty Liver Disease: Practice Guideline by the

American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

12345Naga Chalasani , MD, FACG , Zobair Younossi , MD, FACG , Joel E. Lavine , MD, PhD , Anna Mae Diehl , MD , Elizabeth M. Brunt , MD ,

678

Kenneth Cusi , MD , Michael Charlton , MD and Arun J. Sanyal , MD

Am J Gastroenterol2012; 107: 811 –826; doi: 10.1038/ajg.2012.128; published online 29 May 2012 Preamble De nitions

ese recommendations are based on the following: (i) a formal Th

review and analysis of the recently published world literature on the topic (Medline search up to June 2011); (ii) the Ameri-can College of Physicians ’ Manual for Assessing Health Practices and Designing Practice Guidelines; ( 1 ) (iii) guideline policies of the three societies approving this document; and (iv) the experi-ence of the authors and independent reviewers with regards to non-alcoholic fatty liver disease (NAFLD).

Intended for use by physicians and allied health profession-

als, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. Th ey are intended to be fl exible and adjustable for individual patients. Spe-cifi c recommendations are evidence based wherever possible, and when such evidence is not available or inconsistent, recommenda-tions are made based on the consensus opinion of the authors. To best characterize the evidence cited in support of the recommen-dations, the AASLD Practice Guidelines Committee has adopted the classifi cation used by the GRADE (Grading of Recommenda-tion Assessment, Development, and Evaluation) workgroup with minor modifi cations ( Table 1)( 2). Th e strength of recommenda-tions in the GRADE system is classifi ed as strong (1) or weak (2). Th e quality of evidence supporting strong or weak recommenda-tions is designated by one of three levels: high (A), moderate (B), or low quality (C) ( 2 ). Th is is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently ( 3 – 8 ).

1

e defiTh nition of NAFLD requires that (i) there is evidence of

hepatic steatosis, either by imaging or by histology and (ii) there are no causes for secondary hepatic fat accumulation such as sig-nifi cant alcohol consumption, use of steatogenic medication, or hereditary disorders ( Table 2 ). In the majority of patients, NAFLD is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. NAFLD is histologically further cat-egorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) ( Table 3 ). NAFL is defi ned as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes. NASH is defi ned as the presence of hepatic steatosis and infl ammation with hepatocyte injury (ballooning) with or without fibrosis. Incidence and prevalence in the general population

e incidence of NAFLD has been investigated in a limited number Th

of studies. Two Japanese studies ( 9,10 ) reported an incidence rate of 31 and 86 cases of suspected NAFLD per 1,000 person-years, respectively, whereas another study from England showed a much lower incidence rate of 29 cases per 100,000 person-years ( 11 ). More studies are needed to better understand the incidence of NAFLD across diff erent age, ethnic, and geographic groups. Th e reported prevalence of NAFLD varies widely depending on the population studied and the defi nition used. Th e prevalence of histologically defi ned NAFLD was 20 and 51 % in two diff er-ent studies comprised of potential living liver donors ( 12,13 ).

2

Indiana University School of Medicine , Indianapolis , Indiana , USA ; Department of Medicine, Center for Liver Disease, InovaFairfax Hospital , New York , New

345

York , USA ; Falls Church Columbia University , New York , New York , USA ; Duke University , Durham , North Carolina , USA ; Washington University , St Louis ,

678

Missouri , USA ; University of Florida , Gainesville , Florida , USA ; Mayo Clinic , Rochester , Minnesota , USA ; Virginia Commonwealth University , Richmond , Virginia , USA . Correspondence: Naga Chalasani, MD, FACG , Medicine and Cellular and Integrative Physiology, Director, Division of Gastroenterology & Hepatology, Indiana University School of Medicine , RG 4100, 1050 Wishard Boulevard, Indianapolis , Indiana 46202 , USA . E-mail: nchalasa@iupui.edu Submitted for Governing Board approval by AASLD, ACG, and AGA on 22 February 2012.

This article is being published jointly in 2012 in Gastroenterology , American Journal of Gastroenterology , and Hepatology . Received 4 April 2012; accepted 4 April 2012

© 2012 by the American College of Gastroenterology

The American Journal of GASTROENTEROLOGY

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email